An experimental vaccine or revaccination with primary bacille Calmette-Guérin (BCG) did not protect against tuberculosis (TB) infection in South African adolescents, according to a phase 2 trial published in the New England Journal of Medicine. But participants who received either vaccine had lower rates of sustained QuantiFERON-TB Gold In-tube assay (QFT) conversion, suggesting that they had a lower risk of developing TB.
Slomski A. Study Lays Foundation for TB Vaccine. JAMA. 2018;320(12):1231. doi:10.1001/jama.2018.13872
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: